Sökning: onr:"swepub:oai:DiVA.org:umu-128475" >
Targeted suppressio...
Targeted suppression of AR-V7 using PIP5K1 alpha inhibitor overcomes enzalutamide resistance in prostate cancer cells
-
Sarwar, Martuza (författare)
-
- Semenas, Julius (författare)
- Umeå universitet,Institutionen för molekylärbiologi (Medicinska fakulteten),Division of Experimental Cancer Research, Department of Translational Medicine, Lund University, Clinical Research Centre, Malmö, Sweden
-
- Miftakhova, Regina (författare)
- Umeå universitet,Institutionen för molekylärbiologi (Medicinska fakulteten),Division of Experimental Cancer Research, Department of Translational Medicine, Lund University, Clinical Research Centre, Malmö, Sweden; Department of Genetics, Kazan Federal University, Kazan, Russia
-
visa fler...
-
Simoulis, Athanasios (författare)
-
Robinson, Brian (författare)
-
Wingren, Anette Gjorloff (författare)
-
Mongan, Nigel P. (författare)
-
Heery, David M. (författare)
-
Johnsson, Heather (författare)
-
Abrahamsson, Per-Anders (författare)
-
Dizeyi, Nishtman (författare)
-
Luo, Jun (författare)
-
- Persson, Jenny L. (författare)
- Umeå universitet,Institutionen för molekylärbiologi (Medicinska fakulteten),Division of Experimental Cancer Research, Department of Translational Medicine, Lund University, Clinical Research Centre, Malmö, Sweden
-
visa färre...
-
(creator_code:org_t)
- 2016-08-31
- 2016
- Engelska.
-
Ingår i: Oncotarget. - : Impact Journals, LLC. - 1949-2553. ; 7:39, s. 63065-63081
- Relaterad länk:
-
https://umu.diva-por... (primary) (Raw object)
-
visa fler...
-
http://www.oncotarge...
-
https://urn.kb.se/re...
-
https://doi.org/10.1...
-
visa färre...
Abstract
Ämnesord
Stäng
- One mechanism of resistance of prostate cancer (PCa) to enzalutamide (MDV3100) treatment is the increased expression of AR variants lacking the ligand binding-domain, the best characterized of which is AR-V7. We have previously reported that Phosphatidylinositol-4-phosphate 5-kinase alpha (PIP5K alpha), is a lipid kinase that links to CDK1 and AR pathways. The discovery of PIP5K alpha inhibitor highlight the potential of PIP5K1 alpha as a drug target in PCa. In this study, we show that AR-V7 expression positively correlates with PIP5K1 alpha in tumor specimens from PCa patients. Overexpression of AR-V7 increases PIP5K1 alpha, promotes rapid growth of PCa in xenograft mice, whereas inhibition of PIP5K1 alpha by its inhibitor ISA-2011B suppresses the growth and invasiveness of xenograft tumors overexpressing AR-V7. PIP5K1 alpha is a key co-factor for both AR-V7 and AR, which are present as protein-protein complexes predominantly in the nucleus of PCa cells. In addition, PIP5K1 alpha and CDK1 influence AR-V7 expression also through AKT-associated mechanism dependent on PTEN-status. ISA-2011B disrupts protein stabilization of AR-V7 which is dependent on PIP5K1 alpha, leading to suppression of invasive growth of AR-V7-high tumors in xenograft mice. Our study suggests that combination of enzalutamide and PIP5K1 alpha may have a significant impact on refining therapeutic strategies to circumvent resistance to antiandrogen therapies.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cancer and Oncology (hsv//eng)
Nyckelord
- Prostate cancer metastasis
- enzalutamide resistance
- lipid kinase inhibitor
- AR-V7
- PIP5K1α
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Sarwar, Martuza
-
Semenas, Julius
-
Miftakhova, Regi ...
-
Simoulis, Athana ...
-
Robinson, Brian
-
Wingren, Anette ...
-
visa fler...
-
Mongan, Nigel P.
-
Heery, David M.
-
Johnsson, Heathe ...
-
Abrahamsson, Per ...
-
Dizeyi, Nishtman
-
Luo, Jun
-
Persson, Jenny L ...
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Cancer och onkol ...
- Artiklar i publikationen
-
Oncotarget
- Av lärosätet
-
Umeå universitet